LifeStance Q2 revenue $209.5M (+31%); net loss $68.7M; lowers FY revenue guidance to bottom of $865-885M range

LifeStance Health Group, Inc.

Revenue $209.5M, +31% YoY; net loss $68.7M (incl $57.5M stock comp).
Adjusted EBITDA $14.6M flat YoY; Center Margin $59.8M (28.5% of rev).
Clinicians 5,226 (+31%); net add 237 in Q2; 4 acquisitions closed.
FY2022 rev guidance lowered to bottom of $865-885M; Adj. EBITDA reaffirmed $63-67M; Q3 rev $216-221M.
Danish Qureshi appointed COO effective July 1; OBIE online booking live in 9 states.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.